Veravas, Inc. joins national accelerator to advance heart and brain health
The American Heart Association Heart and Brain Health Accelerator track is part of the larger MedTech Innovator Accelerator Program
AUSTIN, Texas – August 12, 2025 — Veravas, Inc. is among eight health technology companies selected to participate in the latest cohort of the American Heart Association Heart and Brain Health Accelerator. The program is designed to identify and support companies with novel medical or digital health technologies aligned with the lifesaving mission of the American Heart Association.
“We’re thrilled to be part of this year’s Heart and Brain Health Accelerator. With the support of the American Heart Association and its network, we look forward to the opportunity broaden the value we deliver with our VeraBINDTM technology—including the VeraBIND Tau assay, which accurately measures active tau pathology, a key biomarker of Alzheimer’s disease (AD) and other tauopathies, in individuals with and without cognitive impairment,” said John Forrest, Co-Founder, CEO, & Executive Chairman of Veravas. “This opportunity provides meaningful support as we work to address complex challenges in heart and brain health.”
The Accelerator is a collaboration between American Heart Association Ventures™ and the Association’s Center for Health Technology and Innovation. The Association’s Heart and Brain Health Accelerator is one track within the larger MedTech Innovator Accelerator Program.
The eight finalists have specific solutions and applications identified by experts for their potential to positively impact women’s cardiovascular and brain health outcomes. Companies were selected by expert volunteers on an American Heart Association advisory committee.
As a selected company in the track, Veravas now becomes an official member of the Medtech Innovator program for this year, which includes access to networking opportunities, funding and increased visibility within the medical technology industry. In addition, Veravas will receive specialized mentorship, coaching and capacity building from American Heart Association Ventures, customized to its focus on the early detection of Alzheimer’s disease and other neurological conditions.
As participants in the Heart and Brain Health Accelerator, these companies qualify to participate in the MedTech Innovator Competition Finals, held at the MedTech Conference on October 5-8, 2025, in San Diego. Astellas Rx+ sponsors the American Heart Association Heart and Brain Heath Accelerator track.
For more information, visit medtechinnovator.org/mti-aha-track.
###
About Veravas:
Veravas is a leading innovator in clinical diagnostics focused on early-stage detection and prognostic screening for Alzheimer’s disease and other neurological conditions. The company’s proprietary VeraBIND™ technology transforms challenging sample types into measurable biomarkers, enabling improved detection capabilities leading to earlier disease detection and the develop0ment of novel diagnostic assays. Its VeraBIND Tau assay is a first-in-class blood-based test that measures the pathological activity of hyperphosphorylated tau in blood samples of cognitively normal individuals or individuals experiencing cognitive impairment which may be used to aid in the diagnosis of Alzheimer's disease. Learn more at Veravas.com or follow us on LinkedIn.
Media Contact:
Allyson Burroughs
Veravas, Inc.
aburrougs@veravas.com
